Johnson & Johnson's $14.6bn acquisition of Intra-Cellular Therapies adds Caplyta and a robust pipeline targeting major ...

Spotlighting innovation at the SCOPE Summit, finalists for the Site Innovation and Patient Engagement Awards showcase ...

Newly launched company, Verdiva Bio, is aiming to advance oral and injectable drugs for obesity, with it backed by an ...

As India’s contract manufacturing and development organization (CDMO) is set to double in the next decade, Anthem Biosciences ...

Denali Therapeutics' DNL343 fails to slow ALS progression in phase 2/3 trial but shows safety and offers insights for future ...

Orbis Medicines secures €90M Series A to develop innovative oral macrocycles, offering cost-effective alternatives to ...

According to the terms of the deal, Gilead will select a set of drug targets and Terray will discover and develop small molecule drugs that bind to them. Gilead has the option to exclusively license ...

The potential $2.9 billion deal stands the New Jersey company in good stead after recent disappointing results in its ALS program.

The acquisition of Nimble Therapeutics will grant AbbVie access to a pipeline of oral peptide drugs for the treatment of immune diseases including psoriasis and inflammatory bowel disease AbbVie and ...